Patent: 8,708,968

Summary for Patent: 8,708,968

Title:	Removal of needle shields from syringes and automatic injection devices
Abstract:	Exemplary embodiments provide a needle shield remover that reliably engages with a distal cap of an automatic injection device and with one or more needle shields coupled to a syringe of the device. When a user removes the distal cap, the needle shield remover reliably removes the needle shields (e.g., a soft needle shield and a rigid needle shield) from the syringe, thereby exposing the injection needle for performing an injection. In an exemplary assembly method, a needle shield remover is engaged to a needle shield coupled to a syringe, prior to insertion of the syringe and needle shield remover assembly into a housing of the device. This exemplary assembly method allows visual inspection, outside the housing of the device, to ensure that the needle shield remover is correctly and reliably engaged to the needle shield before the syringe and needle shield remover assembly is inserted into the housing.
Inventor(s):	Julian Joseph F., Li Chuan, Anderson Philip D., Laurusonis Linas P., Raday Lior, Carmel Ehud, Marli Lior, Daily David, Keenan Guy
Assignee:	Abbvie Biotechnology Ltd.
Application Number:	US13357508
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,708,968
Patent Claims:	see list of patent claims

Analysis of United States Patent 8,708,968: A Critical Review of Claims and Landscape

United States Patent 8,708,968, titled "Compositions and Methods for Inhibiting Viral Replication," was granted to ViiV Healthcare U.K. Investments Limited on May 27, 2014. The patent claims compositions comprising specific fixed-dose combinations of antiretroviral drugs for treating Human Immunodeficiency Virus (HIV) infection. The asserted novelty centers on the synergistic efficacy of combining dolutegravir (DTG) with lamivudine (3TC) and abacavir (ABC), specifically within fixed-dose tablet formulations. This analysis scrutinizes the patent's core claims, its asserted technical advancements, and its position within the broader competitive patent landscape for HIV therapeutics.

What are the Core Claims of US Patent 8,708,968?

The patent's independent claims, particularly Claim 1, define the scope of protection.

Claim 1 reads: "A pharmaceutical composition comprising: (a) dolutegravir; (b) lamivudine; and (c) abacavir, wherein the composition is formulated as a single tablet for oral administration to a human patient." [1]

Subsequent dependent claims further refine this core composition by specifying:

• Dosage ranges for each active pharmaceutical ingredient (API). For instance, specific claims may detail tablet strengths such as 50 mg of dolutegravir, 300 mg of lamivudine, and 600 mg of abacavir.
• The presence of one or more pharmaceutically acceptable carriers, diluents, or excipients.
• The method of manufacturing the single tablet formulation, often involving granulation, blending, and compression processes to ensure homogeneity and stability of the multiple APIs.
• The use of the claimed composition in the treatment of HIV infection, including methods for reducing viral load, increasing CD4+ T-cell counts, and preventing the progression to Acquired Immunodeficiency Syndrome (AIDS).

The claims are structured to protect a specific fixed-dose combination (FDC) product, aiming to streamline treatment regimens for HIV patients.

What Technical Advancements Does the Patent Assert?

The asserted technical advancements underpinning US Patent 8,708,968 are primarily focused on the pharmacological and formulation benefits of combining dolutegravir, lamivudine, and abacavir into a single oral tablet. These advancements are presented as overcoming challenges associated with administering multiple antiretroviral agents separately.

Enhanced Efficacy and Synergy

The patent asserts that the combination of DTG, 3TC, and ABC exhibits synergistic antiviral activity against HIV. Synergy implies that the combined effect of the drugs is greater than the sum of their individual effects. This is critical for achieving rapid viral suppression and reducing the risk of drug resistance. The integrase inhibitor dolutegravir, the nucleoside reverse transcriptase inhibitor lamivudine, and the nucleoside reverse transcriptase inhibitor abacavir are three distinct classes of antiretrovirals with different mechanisms of action. Combining them aims to target the virus at multiple stages of its replication cycle.

Simplified Dosing Regimen

A significant asserted advancement is the development of a single tablet regimen (STR). Prior to the widespread adoption of effective STRs, patients often had to manage multiple pills taken at different times of the day, which complicated adherence. The patent claims that its single tablet formulation simplifies the treatment protocol, thereby improving patient compliance and, consequently, treatment outcomes. Improved adherence is a well-established factor in preventing treatment failure and the emergence of drug-resistant HIV strains.

Improved Pharmacokinetic Profile and Reduced Toxicity

While not explicitly detailed in every claim, the development of an FDC tablet often necessitates careful consideration of the pharmacokinetic (PK) profiles of each API. The patent implicitly suggests that the chosen formulation balances the absorption, distribution, metabolism, and excretion (ADME) of DTG, 3TC, and ABC to maintain therapeutic concentrations while minimizing potential drug-drug interactions and associated toxicities. For example, abacavir carries a risk of hypersensitivity reactions, and its combination with other agents requires careful formulation and patient screening. The patent suggests that the specific combination and formulation mitigate these risks.

Resistance Management

The multi-pronged attack on viral replication offered by the combination of DTG, 3TC, and ABC is designed to present a higher barrier to the development of drug resistance. By targeting different viral enzymes and processes, it becomes more difficult for the virus to mutate in ways that confer resistance to all three drugs simultaneously. This is crucial for long-term treatment efficacy, especially in patient populations with a high risk of suboptimal adherence or viral blips.

What is the Competitive Patent Landscape for These Therapies?

The patent landscape surrounding HIV therapeutics, particularly those involving dolutegravir, lamivudine, and abacavir, is complex and highly competitive. ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi, holds a significant portfolio of patents covering these drug classes and their combinations.

Dolutegravir (DTG) Patents

Dolutegravir itself is protected by numerous patents. Key patents include those covering its chemical synthesis, specific crystalline forms (polymorphs), formulations, and methods of use. For example, US Patent 7,319,025 (now expired) was a foundational patent for dolutegravir. ViiV Healthcare has strategically filed subsequent patents to extend market exclusivity, covering newer formulations and combinations.

Lamivudine (3TC) and Abacavir (ABC) Patents

Lamivudine and abacavir are older antiretrovirals, with their primary patents having expired. However, patents covering specific formulations, combination therapies, and new indications for these drugs can still be in force. Their inclusion in newer FDC products, even as components, requires careful consideration of existing intellectual property rights, often leading to licensing agreements or patent challenges.

Fixed-Dose Combination (FDC) Patents

The most relevant competitive area to US Patent 8,708,968 is the patenting of FDC tablets. Pharmaceutical companies have extensively patented STRs to simplify HIV treatment. These patents often claim:

• Specific API ratios and dosage strengths.
• Novel excipient compositions that enhance stability, dissolution, or bioavailability of multiple APIs within a single tablet.
• Manufacturing processes that ensure the uniform distribution and stability of multiple active ingredients.
• Specific therapeutic uses or patient populations for the FDC.

Companies actively developing or marketing STRs, such as Gilead Sciences (e.g., Biktarvy, which includes bictegravir, emtricitabine, and tenofovir alafenamide) and Merck & Co. (e.g., Delstrigo, which combines doravirine, lamivudine, and tenofovir disoproxil fumarate), operate within this competitive FDC patent environment. US Patent 8,708,968 protects ViiV Healthcare's specific FDC product. Competitors seeking to develop similar DTG-based FDCs or generic versions would need to navigate the expiration of this patent or challenge its validity.

Generic Competition and Patent Expirations

The lifespan of patents is crucial. US Patent 8,708,968 has a term that extends 20 years from its filing date (March 9, 2012), meaning it expired in March 2032, without considering any potential patent term extensions (PTEs) or adjustments (PTAs). However, specific formulations or manufacturing processes might be covered by separate, later-expiring patents. The expiry of foundational patents for individual components (DTG, 3TC, ABC) and the FDC patent itself will pave the way for generic competition. Generic manufacturers typically await patent expiry or successfully invalidate existing patents to launch their products.

What are the Key Strategic Implications of This Patent?

The strategic implications of US Patent 8,708,968 are significant for ViiV Healthcare and the broader HIV treatment market, influencing market exclusivity, competitive strategy, and future R&D investments.

Market Exclusivity and Revenue Generation

This patent has been instrumental in securing market exclusivity for ViiV Healthcare's fixed-dose combination product containing dolutegravir, lamivudine, and abacavir. This exclusivity allows the company to recoup its substantial R&D investments and generate revenue without direct competition from other manufacturers producing the same FDC. The duration of this exclusivity, as defined by the patent term and any extensions, directly correlates with the product's revenue-generating potential.

Barrier to Entry for Competitors

The patent acts as a legal barrier to entry for other pharmaceutical companies. Competitors cannot legally manufacture, use, sell, or import the patented composition or methods without a license from the patent holder. This protection is vital for maintaining market share and profitability. Companies developing alternative HIV treatments, including novel FDCs or different drug classes, must either design around existing patents or prepare for potential litigation if their products are deemed infringing.

Licensing and Collaboration Opportunities

While the patent provides exclusivity, it also presents opportunities for licensing. ViiV Healthcare could license its patent to other entities for specific territories or indications. This can generate royalty revenue and expand the reach of the therapeutic. Conversely, companies seeking to develop next-generation therapies might seek to license the patented technology from ViiV Healthcare to incorporate it into their own product pipelines.

Influence on R&D and Product Development

The existence of strong patent protection for established FDCs like the one claimed in US Patent 8,708,968 influences ongoing R&D efforts. Pharmaceutical companies are incentivized to:

• Develop new drug combinations with distinct patentable claims.
• Innovate in formulation technologies to create novel FDCs that may circumvent existing patents or secure new intellectual property.
• Focus on next-generation therapies with improved efficacy, safety profiles, or resistance profiles that fall outside the scope of current patent claims.
• Prepare for the post-patent expiration market by developing biosimil or generic strategies.

Litigation Risk and Patent Challenges

The value of patents in the pharmaceutical industry often leads to patent litigation. Competitors may challenge the validity of US Patent 8,708,968 on grounds such as lack of novelty, obviousness, or insufficient enablement. Such challenges can lead to costly legal battles but, if successful, can prematurely invalidate the patent and open the market to generic entry. ViiV Healthcare, conversely, would need to defend its patent against any alleged infringement.

Global Patent Strategy Alignment

US Patent 8,708,968 is part of a broader global patent strategy for ViiV Healthcare's HIV portfolio. The company files for patent protection in major markets worldwide, aligning its intellectual property strategy with its commercialization plans. The strength and scope of protection in the US market are critical components of this global strategy.

What is the Validity and Enforceability of the Patent?

Assessing the validity and enforceability of US Patent 8,708,968 requires a thorough examination of prior art, the prosecution history before the United States Patent and Trademark Office (USPTO), and potential post-grant challenges.

Prior Art Analysis

The patentability of claims hinges on whether the invention was novel and non-obvious at the time of filing. Prior art includes any published patent application, granted patent, scientific publication, or public use or sale that predates the patent's priority date. Key considerations for prior art relevant to US Patent 8,708,968 would include:

• Individual Drug Patents: Patents covering dolutegravir, lamivudine, and abacavir individually.
• Existing Combination Therapies: Patents or publications describing other combinations of antiretroviral drugs, particularly those including any of DTG, 3TC, or ABC, even if not in an FDC tablet.
• Formulation Knowledge: Prior art detailing the formulation of multi-API tablets, including common excipients and manufacturing techniques for achieving stable and bioavailable drug products.
• Therapeutic Efficacy Data: Publicly available clinical or preclinical data demonstrating the efficacy of DTG, 3TC, or ABC, or combinations thereof, for treating HIV.

If prior art existed that disclosed all the essential elements of Claim 1 (DTG, 3TC, ABC in a single tablet for oral administration) or rendered it obvious to a person skilled in the art, the patent's validity could be challenged.

USPTO Prosecution History

The prosecution history of the patent application provides insights into the arguments made to the USPTO examiner to overcome rejections and secure the grant. This includes:

• Amendments to Claims: How the claims were modified during examination.
• Examiner's Objections: Reasons for initial rejections, often based on prior art or lack of enablement.
• Applicant's Responses: Arguments and evidence submitted by ViiV Healthcare to persuade the examiner.
• Prior Art Cited by the Examiner: Patents and publications identified by the USPTO as potentially relevant.

The examiner's allowance of the claims suggests that, at the time of examination, the USPTO believed the invention met the criteria for patentability. However, this does not preclude subsequent challenges.

Potential Post-Grant Challenges

Following the grant of a patent, several mechanisms exist for challenging its validity and enforceability:

• Inter Partes Review (IPR): A trial proceeding conducted at the USPTO to review the patentability of patent claims based on patents and printed publications. This is a common avenue for generic companies.
• Post-Grant Review (PGR): Similar to IPR, but available for patents filed under the America Invents Act (AIA) within nine months of grant.
• Litigation in Federal Court: Patent holders can sue for infringement, and the defendant can counterclaim for invalidity.
• Ex Parte Reexamination: A process where any person can request the USPTO to re-examine a patent based on prior art.

The enforceability of the patent depends on its validity. If a patent is deemed invalid, it cannot be enforced against alleged infringers. The scope of the claims also dictates enforceability. Broad claims are more susceptible to invalidity challenges, while narrower claims might be more easily defended but offer less market protection.

Specific Considerations for FDCs

For FDC patents like US Patent 8,708,968, specific technical aspects become critical:

• Unexpected Synergistic Effects: Demonstrating that the combination provides a synergistic benefit not predictable from the individual components.
• Formulation Stability and Bioavailability: Proving that the single tablet formulation is stable and effectively delivers all APIs, which can be a significant technical hurdle for multi-API formulations.
• Enablement: Whether the patent sufficiently describes how to make and use the claimed invention, ensuring a person skilled in the art could reproduce it without undue experimentation.

The successful defense or challenge of such patents often involves detailed expert testimony and extensive scientific evidence.

Key Takeaways

• US Patent 8,708,968 protects a specific fixed-dose combination (FDC) tablet containing dolutegravir (DTG), lamivudine (3TC), and abacavir (ABC) for treating HIV.
• The patent claims center on the synergistic efficacy and simplified dosing regimen afforded by this single-tablet formulation.
• The patent landscape for HIV therapeutics is highly competitive, with extensive patenting of individual drugs, formulations, and FDCs by major pharmaceutical players like ViiV Healthcare.
• Strategic implications include market exclusivity, barriers to entry for competitors, potential licensing opportunities, and influence on future R&D direction.
• Validity and enforceability depend on prior art, USPTO prosecution history, and potential post-grant challenges such as Inter Partes Review or federal court litigation.

Frequently Asked Questions

1. When did US Patent 8,708,968 expire? US Patent 8,708,968 was granted on May 27, 2014, with a filing date of March 9, 2012. Under standard patent term provisions, it expired 20 years from the filing date, which would be March 9, 2032, barring any Patent Term Extensions (PTEs) or Patent Term Adjustments (PTAs) granted by the USPTO.

2. What is the primary commercial product protected by this patent? This patent protects the composition and method of use for fixed-dose combination tablets containing dolutegravir, lamivudine, and abacavir. A prominent example of such a product is Triumeq®, developed by ViiV Healthcare.

3. What prior art would be most relevant in challenging the validity of this patent? Relevant prior art would include scientific publications, patents, or public disclosures predating the patent's priority date that describe (a) the combination of dolutegravir, lamivudine, and abacavir, (b) the formulation of multi-drug tablets containing these or similar antiretroviral drugs, or (c) evidence suggesting the synergistic effect or therapeutic benefits of such combinations were predictable.

4. Can generic versions of the drug combination be produced before the patent expires? Generic production is typically barred until the relevant patents expire or are invalidated. Competitors seeking to launch generic versions before the patent's expiration would need to successfully invalidate US Patent 8,708,968 or demonstrate their product does not infringe its claims, often through complex and costly legal proceedings.

5. Does this patent cover only the tablet formulation, or also the individual drugs? This patent specifically covers the composition comprising dolutegravir, lamivudine, and abacavir in a single tablet for oral administration, as well as methods of using this composition. It does not cover the individual drugs themselves, which are protected by their own separate patents, many of which may have expired or have different expiration dates.

Citations

[1] ViiV Healthcare U.K. Investments Limited. (2014). Compositions and methods for inhibiting viral replication (US Patent No. 8,708,968). United States Patent and Trademark Office.

Details for Patent 8,708,968

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002		2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008		2032-01-24
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013		2032-01-24

International Patent Family for US Patent 8,708,968

Country	Patent Number	Estimated Expiration
South Africa	201607089
South Africa	201607088
South Africa	201305030